
Peripheral Arterial Disease - Pipeline Insight, 2024
Description
Peripheral Arterial Disease - Pipeline Insight, 2024
DelveInsight’s, “Peripheral Arterial Disease – Pipeline Insight, 2024,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Peripheral Arterial Disease: Overview
Peripheral arterial disease (PAD) is a circulatory problem causing a reduced blood flow through the arteries. This typically reduces blood flow to the extremities manifesting as thigh or calf pain during walking or exertion. Patients with peripheral arterial disease (PAD) have decreased lower extremity arterial perfusion which is commonly referred to as “poor circulation.” In most cases of PAD, atherosclerotic plaques narrow the arterial flow lumen which restricts blood flow to the distal extremity. Reduced blood flow can cause thigh or calf pain with walking due to temporary ischemia of the leg muscles during exertion. PAD affects over 200 million adults worldwide and the incidence of PAD increases to as high as 20% in people over the age of 70. Making the diagnosis of PAD should factor in the patient’s history, physical exam, and objective test results. Blood work may reveal altered renal function and abnormal electrolyte levels. Elevation in CRP, D-dimer and interleukin 6 have been associated with diminished exercise tolerance. Management strategies for PAD attempt to achieve two distinct goals: lower cardiovascular risk and improve walking ability. Once the diagnosis of PVD is made, lifelong follow up is required. The disorder has no cure and if the lifestyle is not modified, the condition progresses.
""Peripheral Arterial Disease - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease treatment guidelines. The assessment part of the report embraces, in depth Peripheral Arterial Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease.
This segment of the Peripheral Arterial Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peripheral Arterial Disease Emerging Drugs
- Semaglutide: Novo Nordisk
- VM202: Helixmith
Further product details are provided in the report……..
Peripheral Arterial Disease: Therapeutic Assessment
This segment of the report provides insights about the different Peripheral Arterial Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Peripheral Arterial Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Peripheral Arterial Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease drugs.
Peripheral Arterial Disease Report Insights
- Peripheral Arterial Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Peripheral Arterial Disease drugs?
- How many Peripheral Arterial Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Arterial Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral Arterial Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peripheral Arterial Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Peripheral Arterial Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
- Comparative Analysis
- Semaglutide: Novo Nordisk
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- AMG0001: AnGes USA, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early stage products (Phase I/II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Peripheral Arterial Disease Key Companies
- Peripheral Arterial Disease Key Products
- Peripheral Arterial Disease- Unmet Needs
- Peripheral Arterial Disease- Market Drivers and Barriers
- Peripheral Arterial Disease- Future Perspectives and Conclusion
- Peripheral Arterial Disease Analyst Views
- Peripheral Arterial Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.